Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

Abstract Background Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; inc...

Full description

Bibliographic Details
Published in:BMC Neurology
Main Authors: Jessica Ailani, Peter McAllister, Paul K. Winner, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Bjørn Sperling, Anders Ettrup, Roger Cady
Format: Article
Language:English
Published: BMC 2022-06-01
Subjects:
Eptinezumab
Migraine
CGRP
MBS
Online Access:https://doi.org/10.1186/s12883-022-02714-1

Internet

https://doi.org/10.1186/s12883-022-02714-1

Similar Items